In this study, network pharmacology findings suggested that the possible mechanism of SGD in AA treatment is through acting on IL-6, PTGS2, TNF, CCL2, IL-1B, IL-10, and other targets, mainly regulating the PI3K-AKT signaling pathway and Jak-STAT signaling pathway, thus exerting anti-inflammatory, immunomodulatory, and antidepressant functions. Here, IL1B is linked to specific granule deficiency.